TG Therapeutics, Inc., was incorporated in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B cell-mediated diseases. Its product BRIUMVI (ublituximab-xiiy) has received regulatory approval in the US, EU and UK for the treatment of adult patients with relapsing multiple sclerosis.
